TORONTO--(BUSINESS WIRE)--Medworxx Solutions Inc. ("Medworxx") (TSX VENTURE: MWX) today announced Gloucestershire Care Services NHS Trust (GCS) has licensed the Medworxx Clinical Criteria Module and Forms and Assessments Module to be deployed across seven community hospitals, covering 260 beds. GCS provides a range of in-patient and out-patient services to Gloucestershire's population of approximately 600,000 people, including nursing, physiotherapy, reablement and adult social care services.
The decision to invest in Medworxx came after two whole- system Clinical Utilisation Review (CUR) audits, commissioned by Gloucestershire CCG, which included a review of bed utilisation across two acute hospitals and seven community hospitals. The current capability to measure the effectiveness of bed utilisation and patient flow on a daily basis across the Gloucestershire health system is limited and not routinely systematic; as such there is also a variance and inconsistency in current data sets that have been deemed unreliable for strategic decisions. The audits identified opportunities for improvement and provided decision makers with the necessary evidence to select the Medworxx Clinical Criteria Module-- designed to provide advanced patient flow analytics in real-time to support improvements in discharge and system-wide integration.
Since the company’s introduction into the UK market in 2011, Medworxx has been working closely with NHS Providers, commissioners and System Resilience Groups to optimise patient flow and discharge. GCS is the first UK community service provider to adopt Clinical Utilisation Review for improving flow and delivering integrated patient centered care outside of acute hospitals.
“We consider Medworxx system as a solution to aid and enhance the flow of patients through our Community Hospitals. We believe it will proactively support our hospital colleagues in having standardised evidence-based criteria so that patient referrals, transfers and continued stays in the seven GCS Community Hospitals are safe and appropriate. The use of objective criteria assessments will help to minimise any variances in decisions that have historically been based on anecdote and subjective opinion,” said Susan Field, Director of Service Transformation, GCS.
“This is an exciting time for Medworxx and for CUR development in the UK. The Medworxx solution will enable regular review of all patients in community hospitals with the purpose of ensuring that admissions meet the hospitals admission criteria, and identify why each patient did not meet these criteria. For the first time, GCS will be able to collect information and data on individual patient progress and discharge planning in real-time,” said Dan Matlow, President and Chief Executive Officer, Medworxx.
Medworxx delivers health information technology solutions to over 400 hospitals internationally; including Canada, France, United States and United Kingdom. Medworxx helps hospitals meet patient flow challenges, and requirements in compliance and education. Medworxx Utilisation Management—flagship of Medworxx Patient Flow that includes electronic bed board and independent assessment components—currently serves 32%of the acute care beds in Canada.
The statements made in this press release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the company’s expectations and projections. The TSX Venture Exchange has not reviewed this press release and neither approved nor disapproved the information contained in this press release.